GPCRs Flashcards

1
Q

What are GPCRs?

A

G-protein coupled receptors. 7TMD which anchor receptors in PM with an EC amino terminus and an IC carboxy terminus. Associate with G proteins, which recognise the fold of the C terminus and match to appropriate G protein groove. Made up of Ga, B and y (trimeric) Ga subunit is needed for downstream signalling inside the cell, binds to a guanine nucleotide.
800 known receptors which can be subclassified according to their structure and how they bind their endogenous agonist.
Ligands include hormones, peptides, neurotransmitters and lipids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the characteristics of each GPCR family?

A

Family 1a: Receptors for catecholamines, opiates. B-adrenoreceptor best studied. Ligand-binding site is buried within TMD, agonist must be small.

Family 1b: Receptors for small peptides, cytokines. Ligand-binding site incorporates N terminus and some residues that are poking out from TMD.

Family 1c: Receptor for larger peptides like LH, TSH, FSH. More complex structure. Receptors have longer amino terminus and Ligand-binding site is further up in N terminus.

Family 2: Receptors contain very little sequence homology to family 1. Ligand-binding site is within the extended NH2 terminus.

Family 3: Receptors such as metabotrophic receptors glutamate and GABA (GABAb exists as a dimer), Ca receptor. Ligand-binding site found within clam shell structure whereby when the ligand binds it snaps shut.

Family 4: Contains odourant receptors, hundreds of examples.

Family 5: Receptors involved in developmental such as Smo and Frizzled. Not yet common drug targets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How does GPCR become active?

A

When the receptor is occupied by an agonist, G protein becomes active. Conformational change in a binding site, giving higher affinity for GTP. GDP replaced by GTP on a subunit. By dissociates and a+GTP can go and activate downstream targets.
Eventually hydrolysis occurs, GDP replaces GTP. Ga is then highly attracted to By, receptor becomes inactive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the different types of Ga subunit?

A

Usually classified according to the a subunit.

  • Ga s: stimulation of adenylyl cyclase. Linked to B-adrenoreceptors in the heart, lungs and smooth muscle
  • Ga olf: regulates a variety of different effectors including src tyrosine kinases
  • Ga o/i: inhibition of adenylyl cyclase
  • Ga t: acts in visual transduction, increases cGMP
  • Ga q: regulates activity of phospholipase Cb to generate IP3
  • Gby: activate a family of potassium channels which leads to hyperpolarisation of neurons and inhibition of neurotransmission. Can also inhibit voltage-gated Ca channels in neurons and endocrine. Opoid receptors uses both function depending on location.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What methods can you use to visualise GPCR signalling?

A

The a subunit is loaded with radioactive GTPyS. The final phosphate group is connected to a sulfate which is non-hydrolysing and permanently bound, so it cannot be broken down to GDP. Purify and quantify a subunits by measuring radioactivity.

Cholera toxin causes ADP ribosylation step, adds a sugar group to Ga s subunit which irreversibly stimulates cAMP production which you can measure.

Pertussis toxin irreversibly inactivates Gai, causing ribosylation as well. Stops the exchange of GDP to GTP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How can you measure GPCR by analysing downstream products?

A

Measure 2nd messenger production (cAMP and Ca). You can buy cheap fluorescent small molecules that can detect Ca. Initially you would only be able to detect Gq in this way, but drug companies have modified receptors so that Ca is their output.
Measure Ca using FLIPR assay whereby cells containing receptor of interest are loaded with calcium indicator dye.

Fluorescent biomarkers - fluorescent engineered proteins that bind to second messengers, measure fluorescence.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the two hypothesises about G protein interactions?

A
  • The G protein is precouplled to the receptor

- The receptor and the G protein only come together when the receptor is activated ‘Collision theory’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How was FRET analysis used to determine whether the G protein’s interaction with the receptor?

A

1) FRET donor put on the G protein, FRET receiver put on the receptor
2) Check that the proteins are expressed and trafficking. Light absorbed by fluorescence and fluorescence emits a different wavelength
3) Both proteins found at the plasma membrane. Look at the fluorescence transfer between the two molecules.
4) In the presence of the agoinst, the amount of fluorescence emitted is decreased, but fluorescence of GPCR increases due to absorbance, increasing FRET. Shows that the protein and receptor are only getting close enough in the presence of the agonist. So not preoccupied.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How can B2-adrenoreceptors have short and long term effects on the heart?

A

A G protein can switch its coupling because of second messenger activity. B2 adrenoreceptors bind to Ga s to increase cAMP but can also cause long term effect in the heart.
So B-adrenoreceptor using Gs to stimulate increased cAMP, leading to activation of PKA through phosphorylation (regulated by cAMP) which can also cause coupling of receptor from Gs to Gi. The By that is released works on Src kinase which leads to MAPK activation.
Therefore:
Gs: PKA leads to short term effects
Gi: MAPK pathway leads to derogatory long-term effects on the heart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How are signalling pathways regulated?

A

Signalling pathway activated by a receptor is context specific, giving greater control over the physiological outcome.

Regulated by scaffold proteins, adaptor proteins, lipids (association with rafts/lipid microdomains), endocytosis, splicing, post-trans modifications.

Regulation through interacting proteins: RAMPS (proteins in PM, can alter pharmacology of G proteins), GSKs, B-arrestins, RGS (regulators of G-protein signalling).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How can the receptor itself regulate signalling?

A

Two ways:

  • Homologous: the receptor acts back on itself to inhibit
  • Heterologous: 1 receptor activated affects another receptor

Both regulate desensitisation of the receptors, restricting signalling.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can GRKs and B-arrestin regulate a receptor [homologous]?

A

Agonist occupies the receptor for a long time/frequently repetitively.
This causes it to recruit a G-protein receptor kinase, a serine/threonine kinase which phosphorylates the receptor.
Phosphorylation affects C terminus so G protein cannot associate with the receptor even if the agonist is present.
Phosphorylation creates a binding site for B-arrestin, a scaffold protein which attracts machinery involved in endocytosis.
Receptor becomes internalised.
C terminus can become dephosphorylated, agonist release from receptor.
THEN
Endosome can fuse with a lysosome for degradation OR
Receptor is recycled back to the membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the different types of GRKs?

A

Different isoforms of GRKs are found in different locations and are regulated differently. Grk2 and 3 are most common and contains a PH domain to bind By subunits. Grk4 has a very restrictive pattern of expression. GRK5 and 6 are found associated with the PM, not well-understood and required for ERK activation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How can you visualise the interactions of GRK and B-arrestin with the receptor?

A

You can track the recruitment of GRK or B-arrestin to the receptor by doing live cell fluorescence imagine using fluorescent tags on each. According to the intensity of FRET, a colour look up table is used to assign an artificial colour system. Red is high intensity and Blue is low intensity.
Interaction requires continued presence of agonist.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is morphine tolerance?

A

After repeated doses of morphine, higher doses are needed to achieve the same pain relief. Continual use of opiates reduces the receptor reserve meaning higher doses give more unpleasant side-effects. Dose-response curve moves to the right.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How were mice used to investigate whether B-arrestin is required for opiate tolerance?

A

Knockout of B-arrestin2 in mouse. Give mouse repeated doses of opoids at high frequency or continual low dose. In WT mouse, analgesia is dramatically reduced over 5 days. In B-arrestin KO, analgesia is maintained over time but by day 9 the dose-response curve for WT has moved to the right.

Conclusion: Desensitization pathway involves B-arrestin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How is DAMCO used to look at how morphine tolerance occurs?

A

DAMGO is a modified version of natural enkephalin peptide that is destruction-resistant and can be used for experiments, has high u-opoid receptor specificity. DAMGO causes considerable internalisation, but by adding morphine, internalisation of receptors is reduced. This is because morphine is like a partial agonist so when it is desensitised it doesn’t undergo proper internalisation, it simply remains on the membrane in an inactive state. Because morphine is not internalised it cannot be resensitized like DAMGO, meaning that it can cause a high tolerance to develop.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How can genetics predispose you to addiction?

A

Natural SNP found in opiate receptors in people predisposed to alcoholism. When WT and mutant receptor are compared, it was found that the SNP had an impact on the ability of morphine to cause receptor internalisation. In mutant there is increased internalisation via a mechanism distinct from that seen with DAMGO in WT receptor. This could mean that some individuals could be resilient to development of morphine tolerance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How can GPCRs be classified according to fate after internalisation?

A

We can classify receptors into groups depending on what happens after internalisation.

  • Class A: Majority. Very rapidly become recycled back to the membrane.
  • Class B: Remain for a long time on endosome, often still able to signal. Important therapeutic pathway.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What do B-arrestins do?

A

-Provide a scaffold for endocytosis to facilitate receptor internalisation
-Can be an adaptor for a E3 ubiquitin ligase to promote ubiquitination in calcium channels and growth factors
-Provide a scaffold for adaptor proteins which can amplify signalling. Their binding domains are diverse.
Src, MAPKs, MAPKKKs, JNK, p38, PI2 kinase Akt can all bind which can regulate diverse functions. Can lead to regulation of transcription to produce long-term changes in cell function.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How can ERK1/2 be activated in a B-arrestin-dependent, G-protein-independent manner using B-adrenoreceptor?

A

Agonist is applied, in the first 5-10mins there is rapid activation of ERKs then a decreased lower level of long-lasting activation. KO of B-arrestin shows that there is a dramatic decrease in the late phase of signalling.
Conclusion: Agonist induces 2 temporally distinct phases of ERK activation
-1st phase: G protein and PKA sensitive and dependent. Transient. Blocked by H89 and Gs KO.
-2nd phase: Delayed onset but prolonged activity. Insensitive to H89, Gs KO. Sensitive to B-arrestin siRNA.

22
Q

How can ERK1/2 be activated without a G protein attached?

A

When you make a mutation in the carboxy terminus of the receptor which prevents Gas associating with the receptor, there is enhanced ERK activation.
So a TYY mutation in GPCR abolishes G protein activation but leaves arrestin-dependent signalling intact.

23
Q

Are mu-opoid receptors biased?

A

DAMGO is biased towards G-protein signalling.
Morphine is biased towards B-arrestin signalling.
Some do both.
Therapeutically, you want the mu-opoid receptors to be biased toward the analgesia pathway through the G-protein pathway.

24
Q

What are the canonical and non-canonical GPCR pathways?

A

Can signal through the canonical pathway by binding to G protein and recruit GRKs and B-arrestin.
Or B-arrestin can contribute towards signalling itself by associating with a variety of kinases that are important in long term signalling.

25
Q

What is the therapeutic impact of B-arrestin dependent signalling?

A

Traditional screening for GPCR-drugs would be the analysis of 2nd messenger. New screens for B-arrestin-dependent signalling (fluorescent, gene reporter) may identify novel pathway selective drugs with valuable therapeutic properties. Looking for drugs that could target membrane translocation and agonist activity.

Unwanted side-effects come from B-arrestin activity, but beneficial effects is due to canonical pathway. The structure of the receptor will determine which one it uses.

26
Q

What PZM21 and how is it found?

A

A potent Gi activator with exceptional selectivity for mu-opoid receptors and minimal B-arrestin recruitment. It was found when 3 million molecules were computationally docked against the mu-opoid receptor structure to identify new scaffolds. PZM21 is more efficacious for analgesia and devoid of respiratory depression.

27
Q

How are GPCRs dynamic?

A

Receptors can adopt multiple conformations. Depending on the ligand, conformation may be different and signalling may be different. Ligand binding locks it into a particular shape.

28
Q

How was B-adrenoreceptor crystallised?

A

B-adrenoreceptor was the first GPCR to be cloned, showing a similar structure to rhodopsin which had already been crystallised. Rhodopsin has N terminus inside and C terminus outside (opposite) and the ligand is permanently bound to the receptor (not dynamic).
GPCRs are difficult to crystallise because of their dynamic properties. B-adrenoreceptor took 15 years, it is expressed at low levels making purification difficult and integral membrane proteins don’t fold properly outside the membrane.
SO… They truncated the C terminus to remove phosphorylation and G protein binding sites. Replaced the intracellular loop (important for protein-protein interactions) with a protein of a similar size, as to stop alteration of size between TMDs. Enzyme T4-lysosome incorporated in the hybrid receptor to crystallise.

29
Q

How did they test the hybrid receptor for ligand binding?

A

Hybrid receptor must be able to have a ligand binding
site which is representative of the normal receptor.

  • Make sure the TMD could still move. Used a fluorescent ligand which will change fluorescence if the environment (TMD) changes. Hybrid receptor has movement of TMD preserved.
  • Inverse agonist stabilises an inactive configuration of the receptor. Prevents it popping into the active state in the absence of ligand. Some TMD are associated with lipid cholesterols which control parts of the membrane the ligand can go into.
30
Q

How are the B1 and B2-adrenoreceptors different?

A

B-adrenoreceptor 2 is known to have more constitutive activity than B-adrenoreceptor 1. Theor structures can be overlayed. The ligand binding site is very similar, both bind noradrenaline. But B-adrenoreceptor 2 has a slightly looser loop which gives more flexibility, which means it is more likely to adopt an active configuration.

31
Q

What is the mu-opoid receptor oligomeric arrangement?

A

Ligand binding site buried amongst the transmembrane domains. Receptors form antiparallel/non-symmetrical dimers at an angle in the crystallisation. Can change whether the receptor signals between G protein pathway or B-arrestin pathway and change localisation of receptor by altering ICDs.

32
Q

What is CNO?

A

Derived from Clozapine (antipsychotic drug). Engineered receptor can bind and be activated by CNO. Mutations have made it completely insensitive to Ach (its natural ligand in muscarinic receptor) but it can still signal to G protein effectively.

33
Q

What are DREADDs?

A

Designer receptors exclusively activated by designer drugs. New aritifical GPCRs which have no natural ligand that will bind and activate it. First will bind to M3 receptor which is coupled to Gq. Screening program using random mutagenesis and evaluating ligand binding. 2 mutations discovered in TMD (TM3 Y to C, TM5 A to G). Created a receptor that would be activated by CNO.

34
Q

How can Diabetes be treated with DREADDs?

A

Type 2 diabetes results from the body’s ineffective use of insulin largely resulting from excess body weight and inactivity. Symptoms: excessive excretion urine, thirst, constant hunger, weight loss, vision changes and fatigue. Over time diabetes can damage heart, blood vessels, eyes, kidneys and nerves.
DREADDs can boost secretion of insulin.
Make a transgenic mouse which they expressed the DREADDs which were targeted to the B-cells of the pancreas.
Conclusion: Increased insulin release and B-cell mass, improved glucose tolerance in obese mice and prevention of experimentally induced diabetes.
Can activate a B-cell by:
-cAMP which controls K channel activity (regulated by ATP) Increased action potential firing, release of insulin.
-Raising Ca to induce release from insulin granules

35
Q

What is the structure-function of GPCRs?

A

Open structure is found at the extracellular face forms the ligand binding domain.
Towards the intracellular face of the receptor the helices become more tightly packed.
Conformational changes are likely to involve rearrangements of multiple interactions between helices.
Changes in interactions of helices at intracellular face will be translated to intracellular loops to regulate signalling via G protein and B-arrestins, explaining agonist specific biased signalling.

36
Q

What are DREADDs used for?

A

DREADD-based chemogenetic tools are now commonly used by neuroscientists to identify the circuitary and cellular signals that specify behaviour, perceptions, emotions, innate drives and motor functions in species ranging from flies to non-human primates.

37
Q

How was dimer formation investigated?

A

Proteins will 7TMD were screened. GABAb was a bit of a problem because it didn’t bind with a G protein. But if you express both genes, GABAb receptor complexes into a coiled coil domain made up of two subunits.
Disulfide bonding on the N terminal shows that mGLuRs, Ca receptor were also dimers.
Interactions between TMS (e,g, D2 receptors, opoid receptors) also used for dimer formation.

Exception to the rule: Dimers can be formed with Mu-opoid receptors or with dOR or kOR.

38
Q

What are biased ligands?

A

Ligands that can selectively trigger one or the other signalling arms (B-arrestin or G protein).
May have therapeutic potential.

Certain receptors are able to couple to more than one type of G protein and specific ligands may promote preferential coupling to one or the other G proteins.
Certain ligands will preferentially recruit one of the 2 isoforms of B-arrestin. Different ligands can engage in different sets of GRKs (4 different types).

39
Q

What are B-arrestin interacting proteins?

A

B arrestin interacting proteins are widely distributed across subcellular compartments with a majority in the cytoplasm and the nucleus. Involved in signal transduction, cellular organisation, nucleic acid binding, metabolic enzymes, chaperones and ion channels.

40
Q

How do the two isoforms of B arrestin interact?

A

Nuclear pool of B-arrestin1 is involved in distinct processes to cytoplasmic pool of B-arrestin1. B-arrestin2 harbors a nuclear export signal which facilitates its nuclear exclusion ensuring isoforms can be simultaneously involved in non-overlapping signalling events.
B-arrestins can form homodimers or heterodimers.

41
Q

How does biased ligand change the signalling pathway?

A

A distinct conformation of the receptor is induced when it is occupied by a biased ligand. These differences in the ligand-binding pocket must in turn lead to corresponding structural rearrangements (different thermodynamics) of the transmembrane helices as well as the intracellular face of the receptor, which will effect the G protein or B-arrestin pathway.

42
Q

What are the best ways to measure biased ligands?

A
  • Assays of receptor-proximal signals to reduce signal contamination
  • Controls for receptor specificity
  • Matching assay conditions
  • Matching assay duration
  • Follow-up studies in orthogonal assay systems
43
Q

How might biased ligands be used therapeutically?

A

Angiotensin II receptor supports signalling through both the G protein and B-arrestin pathways. SII drug is able to induce MAPK activation but not phosphatidylinotitol turnover in the absence of G protein signalling. SII could be used CV disease by exerting renal and vascular effects of a angiotensin receptor blocker but with myocardial contractility and survival provided by B-arrestin.

TRV027 could be helpful in alleviating the burden of symptoms, mortality and rehospitalisation associated with Acute Heart Failure. ACEs and ARBs cannot be used because they can cause prolonged hypotension and reduced cardiac output. Only works when renin-angiotensin is active i.e. in heart failure.

Mu opoid agonists provide powerful analgesia but have symptoms of vomiting, constipation, postoperative ileus, respiratory decompression, sedation, dependence and abuse.

44
Q

Name signalling outcomes resultant from B arrestin activation?

A

Activation of MAPK including ERK1/2, cJun N-terminal kinase (JNK3), p38 kinase, PI3K and Akt.

Receptor internalisation

Desensitisation of G protein signalling.

45
Q

What are agonists?

A

A ligand that initiates a maximal physiological response when it binds to a receptor

46
Q

What are partial agonists?

A

A ligand that gives a submaximal response when it binds to a receptor due to reduced efficacy.

In the presence of an agonist, it can acts as a competitive antagonist.

47
Q

What is a antagonist?

A

A ligand that blocks or dampens the physiological response when it binds to a receptor. Has affinity but no efficacy for a receptor.

48
Q

What is an inverse agonist?

A

A ligand that binds to the same receptor the agonist but stabilises the receptor in the inactive state, reducing the basal response.

49
Q

What is ICUE2?

A

ICUE2 isa live-cell cAMP biosensor used to measure Gs activation efficacy at the B adrenoreceptor. Greater the efficacy of the B adrenoreceptor to activate Gs, the more cAMP will be produced.

50
Q

What is IBMX?

A

Isoxybutylmethylxantin is a phosphatase inhibitor used to test for the presence of inverse agonism. Since the cells are too weak to produce a high basal cAMP level, IBMX prevents cAMP from being broken down so cAMP can accumulate.

51
Q

In an siRNA of B-arrestin2 why might some of the protein still be observed?

A
  • Not all the cells have taken up the transfection containing the siRNA
  • Not waited long enough for the protein to be present
  • HEK cells dividing continually so the next generation won’t contain the transfection

Use CRISPR-Cas9 to KO B-arrestin2 in a transgenic animal.

52
Q

How might Carvedilol be useful in treating heart failure?

A

Carvedilol is a B-adrenergic receptor antagonist. It has found to be an inverse agonist with some partial agonist activity. It has the ability to stimulate phosphorylation of the receptor’s cytoplasmic tail on previously documented GRKs, recruitment of B-arrestin to the B2AR, receptor internalization and activation of ERK1/2. Therefore Carvedilol has a bias towards the GRK/B-arrestin pathway and may be able to provide effective treatment for heart failure.